Background and Purpose-Noncontrast computed tomographic (CT) hypodensities represent an alternative to the CT angiography spot sign (SS) to predict intracerebral hemorrhage (ICH) expansion. However, previous studies suggested that these markers predicted hematoma expansion independently from each other. We investigated whether the integration of SS and hypodensity (HD) improved the stratification of ICH expansion risk. Methods-A single-center cohort of consecutive patients with ICH was retrospectively analyzed. Patients with available CT angiography, baseline, and follow-up noncontrast CT images available were included. Trained readers reviewed all the images for SS and HD presence, and the study population was classified into 4 groups: SS and HD negative (SS−HD−), SS positive only (SS+HD−), HD positive only (SS−HD+), and SS and HD positive (SS+HD+). ICH expansion was defined as hematoma growth >33% or >6 mL. The association between SS and HD presence and ICH expansion was investigated with multivariable logistic regression. Results-A total of 745 subjects qualified for the analysis (median age, 73 years; 54.1% men). The rates of ICH expansion were 9.3% in SS−HD−, 25.8% in SS+HD−, 27.4% in SS−HD+, and 55.6% in SS+HD+ patients (P<0.001). After adjustment for potential confounders and keeping SS−HD− subjects as reference, the risk of ICH expansion was increased in SS+HD− and SS−HD+ patients (odds ratio, 2.93, P=0.002 and odds ratio, 3.02, P<0.001, respectively). SS+HD+ subjects had the highest risk of hematoma growth (odds ratio, 9.50; P<0.001). Conclusions-Integration of SS and HD improves the stratification of hematoma growth risk and may help the selection of patients with ICH for antiexpansion treatment in clinical trials.
I
ntracerebral hemorrhage (ICH) is the deadliest type of stroke and accounts for 10% to 20% of all cerebrovascular events. 1 Up to one third of patients with ICH experience hematoma growth in the first hours after stroke onset. Being potentially preventable and independently associated with unfavorable prognosis, ICH expansion represents an appealing target for acute ICH treatment. 2 Accurate stratification of ICH expansion risk is crucial to identify those patients at highest risk of clinical deterioration because of active bleeding and therefore most likely to benefit from antiexpansion therapies. The computed tomographic angiography (CTA) spot sign (SS) is a robust imaging predictor of hematoma growth, 3, 4 but CTA is not routinely performed in many settings. Noncontrast computed tomography (NCCT) hypodensities (hypodensity[HD]) have been described and validated to be a reliable alternative to SS for the prediction of hematoma expansion. 5 It is notable, however, that these 2 markers predict hematoma growth independently. 6 Therefore, a combined analysis of SS and HD may provide additional yield in the identification of patients with ICH at high risk of active bleeding. We investigated whether the integration of SS and HD improved the stratification of ICH expansion risk. In particular, we tested the hypothesis that patients showing evidence of both SS and HD are at highest risk of hematoma expansion.
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Methods
Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the corresponding author.
Patient Selection
All aspects of this study received institutional review board approval. Informed consent was either obtained by patients, family members, or waived by the institutional review board. Patients were retrospectively selected from a cohort of consecutive patients with ICH admitted at a single academic urban medical center between 1994 and 2015. 6, 7 We included patients with (1) primary ICH diagnosed on NCCT, (2) availability of baseline and follow-up NCCT images performed within 48 hours from onset, and (3) availability of CTA images. We applied the following exclusion criteria: (1) post-traumatic intracranial hemorrhage, (2) secondary cause of the hemorrhage such as vascular or neoplastic intracranial lesions, (3) evidence of ischemic stroke with hemorrhagic transformation, (4) primary intraventricular hemorrhage, (5) surgical hematoma evacuation before follow-up NCCT, and (6) missing clinical and demographic data.
Clinical Variables
Clinical and demographic data were acquired through patient or family members' interviews or with retrospective review of hospital charts. The following variables were collected: medical history of hypertension, diabetes mellitus, antithrombotic treatment (antiplatelet therapy, oral anticoagulant treatment), statin treatment, admission systolic and diastolic blood pressures, Glasgow Coma Scale score, and time from symptom onset to baseline NCCT. Blood pressure was managed according to the American Heart Association/American Stroke Association guidelines. 8 
Image Acquisition
Baseline and follow-up NCCT scans were obtained with an axial technique (5-mm slice thickness reconstruction), with the following acquisition parameters: tube potential range 120 to 140 kVp, tube current range 100 to 500 mA. Baseline and follow-up ICH volumes on NCCT images were calculated with a semiautomated computerassisted technique (Analyze Direct 11.0 software). All patients underwent a follow-up NCCT scan at 24 hours from onset or earlier in case of clinical deterioration.
First pass CTA images were obtained scanning from the base of the skull to the vertex using an axial technique with the following acquisition parameters: 0.5 pitch, 1.25-mm collimation, 100 to 140 kV(p), with a tube current ranging from 80 to 630 mA. Intravenous iodinated contrast material was administered by a power injector at 4 to 5 mL/s with semiautomatic contrast bolus triggering technique. 
Images Analysis
Two raters (A.M., Stroke Neurologist and G.B., Neuroradiologist) blinded to clinical data, and results of follow-up NCCT reviewed all the CTA and NCCT images for the presence of SS and HD, according to previously described criteria. 5, 6, 9 All discrepancies in SS and HD detection were resolved with joint analysis of images to reach a consensus and make a final decision. Briefly, the SS was defined as presence of at least one focus of contrast pooling within the hemorrhage, with an attenuation ≥120 Hounsfield units and lack of connection with normal or abnormal vessels surrounding the hemorrhage. 9 Hypodensities were defined as presence of any hypodense region inside the hematoma having any morphology and size, disconnected from the surrounding brain parenchyma.
The study population was classified into 4 groups according to the presence of the 2 markers of hematoma expansion: SS and HD negative (SS−HD−); SS positive and HD negative (SS+HD−); SS negative and HD positive (SS−HD+), and SS positive and HD positive (SS+HD+).
An illustrative example of SS+HD+ subject is provided in Figure  I in the online-only Data Supplement.
The main outcome of our analysis was hematoma expansion defined as absolute hemorrhage growth >6 mL or relative hemorrhage growth >33% from baseline ICH volume. 10 In a secondary analysis, a different definition of hematoma expansion was used (absolute hemorrhage growth >12.5 mL or relative hemorrhage growth >33%).
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Statistical Analyses
Continuous variables were expressed as median (interquartile range) or mean (SD) as appropriate based on their distribution evaluated with the Shapiro-Wilk test.
Categorical variables were summarized as count (percentage). Continuous variables with normal and non-normal distribution were compared using the t test/ANOVA and Mann-Whitney/ Kruskal-Wallis test, respectively. Differences in categorical variables were explored with χ 2 test. The interrater reliability for SS and HD identification was assessed with Cohen κ statistic. A multivariable binary logistic regression model was used to investigate the association between the imaging markers of interest and ICH expansion. We adjusted all the regression models for predictors of hematoma expansion already known from the literature, such as baseline ICH volume, anticoagulant treatment, and time from onset to baseline NCCT (model 1), 11 and also for variables with a P<0.1 in univariate analysis (model 2). We calculated every single patients' predicted probability of ICH growth using individual data combined with the binary logistic regression model estimates. The predicted probability of ICH expansion was expressed as a continuous variable ranging from 0 to 1. Finally, we calculated the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for ICH expansion for different SS and HD combinations. P<0.05 was considered statistically significant, and the statistical package SPSS version 21, 2012 (www.spss.com), was used for all the analyses.
Results
A total of 745 subjects were included in the analysis (median age, 73 years; 54.1% men) of whom 148 (19.9%) had significant hematoma expansion. The main reasons for exclusion from the study were as follows: CTA images not available (n=315), missing baseline/follow-up NCCT scan or poor quality images (n=251), and NCCT scans obtained after 48 hours from symptom onset (n=30).
The clinical and demographic characteristics of the selected study population are summarized in Table 1 . Compared with the included subjects, excluded patients had smaller ICH volumes but a higher mortality at 90 days, likely because of the observed higher rate of warfarin treatment, hematoma expansion, intraventricular hemorrhage, and infratentorial bleedings. Excluded patients were also less likely to be on antiplatelet treatment. All the remaining demographic, clinical, and imaging characteristics were similar (all P>0.20) . The comparison between included versus excluded patients is summarized in Table I in the online-only Data Supplement.
We have also compared the prevalence of HD and ICH expansion in patients with CTA images available versus patients who did not receive a CTA and observed no significant differences (HD frequency 29.9% versus 32.3%, P=0.450 and ICH expansion frequency 20.0% versus 21.8%, P=0.530 in patients with versus without CTA, respectively).
The interrater agreement for SS and HD identification was good (κ=0.83, 95% CI, 0.76-0.89 and κ=0.87, 95% CI, 0.87-0.97for SS and HD, respectively). Table 2 shows the clinical and imaging differences between the 4 study groups. SS+HD+ patients were more severely affected, as highlighted by lower admission Glasgow Coma Scale score, larger ICH volumes, and higher rate of intraventricular hemorrhage and mortality at 3 months. Individuals in this group had a shorter time from onset to baseline NCCT and were also more likely to be on warfarin treatment. The hematoma expansion rate was significantly higher in SS+HD− (25.8%) or SS−HD+ (27.4%) when compared with SS−HD− (9.3%). SS+HD+ showed the highest rate of hematoma expansion (51.5%). Table 3 shows the results of the multivariable logistic regression analysis for ICH expansion. After adjustment for known predictors of hematoma expansion, the presence of SS or HD was independently associated with higher odds of ICH expansion (odds ratio, 2.93, P=0.002 for SS+HD− and odds ratio, 3.02, P<0.001 for SS−HD+) when compared with patients with neither of these markers. Patients with combined presence of SS and HD had the highest risk of ICH expansion (odds ratio, 9.50, P<0.001 for SS+HD+). The Figure shows the predicted probability of ICH expansion stratified by SS and HD status.
These results remained significant when other potential confounders were included in the multivariable logistic regression analysis (Table 3 , model 2). We also confirmed all these findings in multiple sensitivity analyses: (1) using a different definition of ICH expansion (hematoma growth >33% or >12.5 mL), (2) excluding warfarin-associated hemorrhages, (3) restricting the logistic regression analysis to early presenters (time from onset to baseline NCCT ≤6 hours), (4) excluding subjects with unknown time from onset to baseline NCCT, and (5) adjusting for hypertension, admission systolic blood pressure, and diastolic blood pressure in the multivariable logistic regression model. Table 4 shows the test characteristics of SS and HD alone compared with potential combinations of the 2 markers.
Discussion
The main finding of this retrospective analysis is that the integration of SS and HD provides additional yield in the stratification of ICH expansion risk. In particular, patients with combined presence of SS and HD are at highest risk of ICH expansion, with an ICH expansion rate >5× higher than subjects with neither of these markers. We also directly compared the diagnostic performance of SS and HD, showing that HD has higher sensitivity for ICH expansion whereas specificity was superior for SS.
Optimal stratification of hematoma expansion risk is a critical component of patient selection in clinical trials aiming at limiting the extent of bleeding in the acute phase of ICH. In one large international clinical trial, <20% of patients with ICH received an early CTA, and intensive blood pressure reduction did not decrease the risk of ICH expansion. 12 In addition, the predictive performance of the SS in this minority of patients was poor, suggesting the need for imaging predictors of hematoma growth that do not require a CTA. Several NCCT markers of hematoma expansion, such as the blend sign, black hole sign, and hematoma density and shape, have been described. 5, [13] [14] [15] Unfortunately, the relationship between SS and NCCT markers of ICH expansion remains poorly characterized. One study has investigated the interaction and clinical yield of integrating the blend sign, an NCCT predictor of hematoma growth, with the SS. 16 In this analysis, the majority of patients with an SS were also blend sign positive, and when included in the same logistic regression analysis, the SS was no longer a significant predictor of ICH expansion. This may indicate that CTA SS is simply ICH expansion was defined as hematoma growth >33% or >6 mL. DBP indicates diastolic blood pressure; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; HD, hypodensity; IQR, interquartile range; IVH, intraventricular hemorrhage; NCCT, noncontrast computed tomographic scan; SBP, systolic blood pressure; and SS, spot sign.
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an epiphenomenon of the NCCT marker blend sign (or vice versa), and the combination of the 2 radiological signs does not improve the prediction of hematoma growth in patients with ICH. Conversely, we showed that SS and HD predict hematoma growth independently from each other, and their integrated analysis identifies patients at highest risk of ICH expansion. These results may be particularly relevant in the setting of study design of future clinical trials testing antiexpansion therapies. The presence of SS+HD+ may mark those patients most likely to benefit from antiexpansion therapies, therefore maximizing statistical power to detect a superior treatment. Conversely, the lack of SS and HD identifies patients with the lowest risk of ICH expansion and therefore less likely to derive benefit from acute therapies targeting hematoma growth.
The combined evidence of SS and HD predicted hematoma expansion with good positive predictive value and excellent specificity. This restrictive selection strategy (<15% of patients with ICH were SS+HD+ in our cohort) may be more appropriate for clinical trials testing antiexpansion therapies with potential to harm, such as hemostatic drugs with thrombotic side effects. A more inclusive definition such as the presence of SS and HD in any combination identified patients at risk of hemorrhage growth with high sensitivity and excellent negative predictive value. This approach seems ideal for antiexpansion therapies with low risk of harm, such as intensive blood pressure reduction or administration of tranexamic ICH expansion was defined as hematoma growth >33% or >6 mL. DBP indicates diastolic blood pressure; GCS, Glasgow Coma Scale; HD, hypodensity; ICH, intracerebral hemorrhage; IQR, interquartile range; IVH, intraventricular hemorrhage; NCCT, noncontrast computed tomographic scan; SBP, systolic blood pressure; and SS, spot sign. ICH expansion was defined as hematoma growth >33% or >6 mL. GCS indicates Glasgow Coma Scale; HD, hypodensity; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; NCCT, noncontrast computed tomographic scan; OR, odds ratio; and SS, spot sign. *Adjusted for baseline ICH volume, time from onset to NCCT, and anticoagulant treatment.
†Adjusted for baseline ICH volume, time from onset to NCCT, anticoagulant treatment, antiplatelet treatment, GCS, and presence of IVH.
acid, to include as many patients as possible at risk of further bleeding. [17] [18] [19] [20] Our findings may also have important implications for ICH care in clinical practice because hematoma expansion is one of the main determinants of clinical deterioration in the early phase of ICH natural history. 21 Subjects at high risk of ICH growth could be selected for more intensive neurological monitoring. In addition, as minimally invasive surgery techniques become available, patients at low risk of hematoma expansion may be more suitable for surgical hematoma evacuation because of a lower risk of postoperative rebleeding.
Although HD and SS are robust and validated predictors of ICH expansion, the biological mechanisms underlying these imaging signs remain poorly characterized and deserve further studies. One possible explanation for HD pathophysiology is the direct relationship between the degree of blood coagulation and hematoma density on computed tomography. 22 HD may indeed represent regions of noncoagulated blood from an actively bleeding site in hemorrhages at a early stage of development. In line with this hypothesis, HD presence is associated with shorter time from onset to NCCT and warfarin-related coagulopathy. 6 Similarly, previous studied reported a strong association between anticoagulant therapy and SS presence 23 and also described a higher rate of iodine contrast extravasation in patients experiencing hematoma growth, indirectly supporting the theory that SS reflects active bleeding. 24 However, in SS+HD+ patients, we observed a clear spatial correspondence between the 2 markers in less than half of the subjects, 6, 13 raising the hypothesis that SS and HD may not represent the same pathophysiological process.
Some limitations should be considered in the interpretation of our results. First, although based on a large, well-characterized ICH cohort, our findings derive from a nonrandomized, single-center retrospective analysis, and prospective confirmation is required. Prospective data collection for independent, external validation of our findings is currently ongoing. Second, a significant proportion of patients were excluded from the analysis because of missing NCCT or CTA images, introducing a potential bias. CTA and follow-up NCCT scan may have been avoided because of withdrawal of care, in particular in patients with warfarin-associated hemorrhages (and therefore at high risk of Figure. Predicted probability of intracerebral hemorrhage (ICH) expansion. P value for trend was calculated with the Jonckheere-Terpstra test. ICH expansion was defined as hematoma growth >33% or >6 mL. HD indicates hypodensity; SS, spot sign. Comparison of the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy percentages between the 4 groups was performed by using the χ 2 test. ICH expansion was defined as hematoma growth >33% or >6 mL. HD indicates hypodensity; ICH, intracerebral hemorrhage; NPV, negative predictive value; PPV, positive predictive value; and SS, spot sign.
September 2018 hematoma growth), leading to potential underestimation of the association between SS, HD, and hemorrhage expansion. This hypothesis is indirectly supported by the observed higher prevalence of infratentorial, warfarin-associated hemorrhages with intraventricular bleeding in the excluded study population. Early limitation of care may have included avoidance of antiexpansion therapies, such as intensive blood pressure lowering and coagulopathy reversal, 25 explaining therefore the higher rate of ICH expansion and mortality in the excluded patients.
Third, different definitions of SS have been reported, and the use of other criteria for SS detection may change our results. 3 In addition, we have analyzed only first pass CTA images for SS detection. Multiphase CTA may improve the recognition of SS and therefore modify our findings. 26 Fourth, the subjects included were enrolled over a long time course with several changes in the NCCT and CTA scanners and acquisition protocols that may have influenced our analysis. 9 Likewise, blood pressure management in acute ICH has significantly changed in the past 2 decades, and this may have had an impact on our results as well. 27 Fifth, the integration of other NCCT predictors of hematoma expansion with the SS or the combination of multiple NCCT markers may have different test characteristics. Finally, NCCT and CTA scans were analyzed by raters with extensive experience in imaging markers of ICH expansion. It remains to be determined whether SS and HD can be reliably and accurately detected by untrained clinicians that are not familiar with acute ICH neuroimaging, especially considering the lack of consensus criteria for identification of NCCT markers of expansion, with significant overlap between different signs.
Conclusions
The combined analysis of SS and HD improves the stratification of ICH expansion risk. This may help the selection of patients for clinical trials testing antiexpansion treatments.
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